


Please place a plus sign (+) inside this box → ☐


Approved for use through 10/31/02. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/052,832
	Filing Date	January 15, 2002
	First Named Inventor	Gregory R. MUNDY
	Group Art Unit	1627
	Examiner Name	Ralph J. Gitomer
Total Number Of Pages In This Submission	Attorney Docket No.	432722002612

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Exhibits A-K Return postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement; PTO form 1449; and 17 references	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	 <b>25225</b> PATENT, TRADEMARK OFFICE
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT	
Firm or Individual Name	Peng Chen Registration No. 43,543
Signature	
Date	July 29, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on July 29, 2002.
 Rhea Amid

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



Docket No. 432722002612

RECEIVED  
PATENT  
AUG 07 2002  
TECH CENTER 1600/2900  
7  
B  
8/30/02

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

Whereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on July 29, 2002.

*Rhea Amid*  
Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Gregory R. MUNDY, et al.

Serial No.: 10/052,832

Filing Date: January 15, 2002

For: INHIBITORS OF PROTEASOMAL  
ACTIVITY FOR STIMULATING  
[BONE AND] HAIR GROWTH (AS  
AMENDED)

Examiner: GITOMER, Ralph J.

Group Art Unit: 1627

AMENDMENT AND RESPONSE UNDER 37 C.F.R. §1.111

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This is in response to the Office Action mailed April 29, 2002 for which a response is due on July 29, 2002. Careful consideration has been given to the grounds for rejection as contained in the Office Action, and the enclosed discussion is offered in response. Also enclosed herewith are the following exhibits:

Exhibit A: A mark-up version of the amended specification and claim 60;

Exhibit B: A copy of Declaration of George L. Mundy pursuant to 37 C.F.R. § 1.132 with the Figures 1-12 and Table 1, which was filed with the July 30, 2001 Amendment in connection with U.S. Serial No. 09/361,775;

Exhibit C: U.S. Patent No. 6,117,887;  
Exhibit D: U.S. Patent No. 6,075,150;  
Exhibit E: U.S. Patent No. 5,847,076;  
Exhibit F: Furet et al., *Bioorg. Med. Chem. Lett.*, 11(10):1321-4 (2001) (Abstract only);  
Exhibit G: Sunwoo et al., *Clin. Cancer Res.*, 7(5):1419-28 (2001) (Abstract only);  
Exhibit H: Sun et al., *Cancer Res.*, 61(4):1280-4 (2001) (Abstract only);  
Exhibit I: Princiotta et al., *Proc. Natl. Acad. Sci. U.S.A.*, 98(2):513-8 (2001) (Abstract only);  
Exhibit J: U.S. Patent No. 5,693,617; and  
Exhibit K: Meng et al., *Proc. Natl. Acad. Sci. U.S.A.*, 96(18):10403-8 (1999).